Abstract
Purpose
The αvβ3 integrin is expressed in angiogenic vessels and is a potential target for molecular imaging of evolving pathological processes. Its expression is upregulated in cancer lesions and metastases as well as in acute myocardial infarction (MI) as part of the infarct healing process. The purpose of our study was to determine the feasibility of a new imaging approach with a novel 68Ga-2,2′,2″-(1,4,7-triazonane-1,4,7-triyl)triacetic acid (NOTA)-arginine-glycine-aspartic acid (RGD) construct to assess integrin expression in the evolving MI.
Methods
A straightforward labelling chemistry to attach the radionuclide 68Ga to a NOTA-based chelating agent conjugated with a cyclic RGD peptidomimetic is described. Affinity for αvβ3 integrin was assessed by in vitro receptor binding assay. The proof-of-concept in vivo studies combined the 68Ga-NOTA-RGD with the flow tracer 13N-NH3 imaging in order to obtain positron emission tomography (PET)/CT imaging of both integrin expression and perfusion defect at 4 weeks after infarction. Hearts were then processed for immunostaining of integrin β3.
Results
NOTA-RGD conjugate displayed a binding affinity for αvβ3 integrin of 27.9 ± 6.8 nM. 68Ga-NOTA-RGD showed stability without detectable degradation or formation of by-products in urine up to 2 h following injection in the rat. MI hearts exhibited 68Ga-NOTA-RGD uptake in correspondence to infarcted and border zone regions. The tracer signal drew a parallel with vascular remodelling due to ischaemia-induced angiogenesis as assessed by immunohistochemistry.
Conclusion
As compared to similar imaging approaches using the 18F-galacto-derivative, we documented for the first time with microPET/CT imaging the 68Ga-NOTA-RGD derivative that appears eligible for PET imaging in animal models of vascular remodelling during evolving MI. The simple chemistry employed to synthesize the 68Ga-based radiotracer may greatly facilitate its translation to a clinical setting.
Similar content being viewed by others
References
Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89:2183–9.
Ren G, Dewald O, Frangogiannis NG. Inflammatory mechanisms in myocardial infarction. Curr Drug Targets Inflamm Allergy 2003;2(3):242–56.
Wu JC, Chen IY, Wang Y, Tseng JR, Chhabra A, Salek M, et al. Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation 2004;110:685–91.
Higuchi T, Bengel FM, Seidl S, Watzlowik P, Kessler H, Hegenloh R, et al. Assessment of αvβ3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res 2008;78:395–403.
Horton MA. The alpha ν beta 3 integrin “vitronectin receptor”. Int J Biochem Cell Biol 1997;29:721–5.
Arnaout MA, Goodman SL, Xiong JP. Coming to grips with integrin binding to ligands. Curr Opin Cell Biol 2002;14:641–51.
Auzzas L, Zanardi F, Battistini L, Burreddu P, Carta P, Rassu G, et al. Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides. Curr Med Chem 2010;17(13):1255–99.
Schottelius M, Laufer B, Kessler H, Wester H-J. Ligands for mapping αvβ3-integrin expression in vivo. Acc Chem Res 2009;42(7):969–80.
Liu Z, Niu G, Shi J, Liu S, Wang F, Liu S, et al. (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging 2009;36:947–57.
Beer AJ, Kessler H, Wester H-J, Schwaiger M. PET imaging of integrin alphaνbeta3 expression. Theranostics 2011;1:48–57.
Gaertner FC, Kessler H, Wester H-J, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging 2012;39 Suppl 1:S126–38.
Belvisi L, Bernardi A, Checchia A, Manzoni L, Potenza D, Scolastico C, et al. Potent integrin antagonist from a small library of RGD-including cyclic pseudopeptides. Org Lett 2001;3:1001–4.
Belvisi L, Riccioni T, Marcellini M, Vesci L, Chiarucci I, Efrati D, et al. Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. Mol Cancer Ther 2005;4:1670–80.
Arosio D, Manzoni L, Araldi EMV, Caprini A, Monferini E, Scolastico C. Functionalized cyclic RGD peptidomimetics: conjugable ligands for ανβ3 receptor imaging. Bioconjug Chem 2009;20:1611–7.
Manzoni L, Belvisi L, Arosio D, Bartolomeo MP, Bianchi A, Brioschi C, et al. Synthesis of Gd and (68)Ga complexes in conjugation with a conformationally optimized RGD sequence as potential MRI and PET tumor-imaging probes. ChemMedChem 2012;7(6):1084–93.
Lanzardo S, Conti L, Brioschi C, Bartolomeo MP, Arosio D, Belvisi L, et al. A new optical imaging probe targeting ανβ3 integrin in glioblastoma xenografts. Contrast Media Mol Imaging 2011;6:449–58.
Pilkington-Miksa M, Arosio D, Battistini L, Belvisi L, De Matteo M, Vasile F, et al. Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery. Bioconjug Chem 2012;23(8):1610–22.
Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ, et al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med 2008;49(5):830–6.
Haukkala J, Laitinen I, Luoto P, Iveson P, Wilson I, Karlsen H, et al. 68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging 2009;36(12):2058–67.
Li X, Samnick S, Lapa C, Israel I, Buck AK, Kreissl MC, et al. 68Ga-DOTATATE PET/CT for detection of inflammation of large arteries: correlation with 18F-FDG, calcium burden and risk factors. EJNMMI Res 2012;2:52.
Tarkia M, Saraste A, Saanijoki T, Oikonen V, Vähäsilta T, Strandberg M, et al. Evaluation of 68Ga-labeled tracers for PET imaging of myocardial perfusion in pigs. Nucl Med Biol 2012;39:715–23.
Ocak M, Antretter M, Knopp R, Kunkel F, Petrik M, Bergisadi N, et al. Full automation of (68)Ga labelling of DOTA-peptides including cation exchange prepurification. Appl Radiat Isot 2010;68(2):297–302.
Teitelbaum SL. Osteoclasts, integrins, and osteoporosis. J Bone Miner Metab 2000;18:344–9.
Del Guerra A, Bartoli A, Belcari N, Herbert D, Motta A, Vaiano A, et al. Performance evaluation of the fully engineered YAP-(S)PET scanner for small animal imaging. IEEE Trans Nucl Sci 2006;53(3):1078–83.
Panetta D, Belcari N, Del Guerra A, Bartolomei A, Salvadori PA. Analysis of image sharpness reproducibility on a novel engineered micro-CT with variable geometry and embedded recalibration software. Phys Med 2012;28:166–73.
Moehrs S, Defrise M, Belcari N, Del Guerra A, Bartoli A, Fabbri S, et al. Multi-ray-based system matrix generation for 3D PET reconstruction. Phys Med Biol 2008;53:6925–45.
Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003;2(3):131–7.
Manzoni L, Belvisi L, Arosio D, Civera M, Pilkington-Miksa M, Potenza D, et al. Cyclic RGD-including functionalized azabicycloalkane amino acids as potent integrin antagonists for tumor targeting. ChemMedChem 2009;4:615–32.
Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, et al. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res 2007;27:4087–94.
Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011;41:314–21.
Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 2004;113:1684–91.
Kalinowski L, Dobrucki LW, Meoli DF, Dione DP, Sadeghi MM, Madri JA, et al. Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction. J Appl Physiol 2008;104:1504–12.
Dobrucki LW, Meoli DF, Hu J, Sadeghi MM, Sinusas AJ. Regional hypoxia correlates with the uptake of a radiolabeled targeted marker of angiogenesis in rat model of myocardial hypertrophy and ischemic injury. J Physiol Pharmacol 2009;60 Suppl 4:117–23.
Sherif HM, Saraste A, Nekolla SG, Weidl E, Reder S, Tapfer A, et al. Molecular imaging of early αvβ3 integrin expression predicts long-term left-ventricle remodeling after myocardial infarction in rats. J Nucl Med 2012;53(2):318–23.
Gao H, Lang L, Guo N, Cao F, Quan Q, Hu S, et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AIF-NOTA-PRGDD2. Eur J Nucl Med Mol Imaging 2012;39:683–92.
Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting αvβ3 integrin expression, in a patient after acute myocardial infarction. Eur Heart J 2008;29(18):2201.
Acknowledgments
This work was supported by the Consiglio Nazionale delle Ricerche, Italy (grant CNR-DG.RSTL.035.007-035), Scuola Superiore Sant’Anna, Italy (grant PNAZ.M6010AL).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 669 kb)
Rights and permissions
About this article
Cite this article
Menichetti, L., Kusmic, C., Panetta, D. et al. MicroPET/CT imaging of αvβ3 integrin via a novel 68Ga-NOTA-RGD peptidomimetic conjugate in rat myocardial infarction. Eur J Nucl Med Mol Imaging 40, 1265–1274 (2013). https://doi.org/10.1007/s00259-013-2432-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-013-2432-9